Last reviewed · How we verify
NCT07076030
Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function
Phase 1 trial testing Petrelintide in Renal Impairment in 39 participants. Completed in 25 November 2025.
25 November 2025
Quick facts
| Lead sponsor | Zealand Pharma |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 39 |
| Start date | 15 April 2025 |
| Primary completion | 25 November 2025 |
| Estimated completion | 25 November 2025 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Petrelintide — full drug profile →
Conditions studied
- Renal Impairment — all drugs for Renal Impairment →
Sponsor
Zealand Pharma — full company profile →
Who can join
Adults 18 to 65, any sex, with Renal Impairment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical research study is testing the study compound petrelintide that is being developed for the weight management in people with obesity or overweight with comorbidities or related diseases. The aim of this clinical research study is to investigate whether the effects of petrelintide will be different in people with normal kidney function compared to people with impaired kidney function.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07076030
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Petrelintide
Trials testing the same drug.
- NCT07338214 — Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations · Phase 1 · completed
- NCT06926842 — Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) · Phase 2 · active not recruiting
- NCT06662539 — Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities · Phase 2 · completed
Other recruiting trials for Renal Impairment
Currently open trials in the same condition.
- NCT07348237 — A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006) · Phase 1 · recruiting
- NCT07315360 — A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function · Phase 1 · recruiting
- NCT07217886 — A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls · Phase 1 · recruiting
- NCT07154901 — Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD23 · Phase 1 · recruiting
- NCT07017933 — Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes · NA · recruiting
Other Zealand Pharma trials
Trials by the same sponsor.
- NCT07197944 — Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS · Phase 3 · recruiting
- NCT07338214 — Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations · Phase 1 · completed
- NCT07228403 — Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome · Phase 3 · enrolling by invitation
- NCT06926842 — Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) · Phase 2 · active not recruiting
- NCT06758583 — A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07076030 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zealand Pharma
- Last refreshed: 28 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07076030.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing